Cookies?
Library Header Image
LSE Research Online LSE Library Services

The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease

Jaffray, Mariesha and Bond, Christine M. and Watson, M. C. and Hannaford, Philip and Tinelli, Michela and Scott, A. and Lee, A. and Blenkinsopp, Alison and Anderson, Cameron and Avery, Anthony and Bissell, P. and Krksa, J. (2007) The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Family Practice, 24 (2). pp. 189-200. ISSN 0263-2136

Full text not available from this repository.

Identification Number: 10.1093/fampra/cml075

Abstract

Background. There have been recent moves to extend the role of the community pharmacist to include medicine management. Methods. A randomized controlled trial was conducted in nine sites in England. Patients with coronary heart disease were identified from general practice computer systems, recruited and randomized (2:1) to intervention or control. The 12-month intervention comprised an initial consultation with a community pharmacist to review appropriateness of therapy, compliance, lifestyle, social and support issues. Control patients received standard care. The primary outcome measures were appropriate treatment [derived from the National Service Framework (NSF)], health status (SF-36, EQ-5D) and an economic evaluation. Secondary outcome measures were patient risk of cardiovascular death and satisfaction. Results. The study involved 1493 patients (980 intervention and 513 control), 62 pharmacists and 164 GPs. No statistically significant differences between intervention and control groups were shown at follow-up for any of the primary outcome measures such as numbers on aspirin or lifestyle measures. There were few differences in quality of life (SF-36) between the intervention and control groups at baseline or follow-up or with overall EQ-5D score over time. The total National Health Service cost increased between baseline and at 12 months in both groups but to a greater extent in the intervention group. Significant improvements were found in the satisfaction score for patients' most recent pharmacy visit for prescription medicines among the intervention group, compared with control group. Self-reported compliance was good for both groups at baseline and no significant differences were shown at follow-up. Conclusion. There was no change in the proportion of patients receiving appropriate medication as defined by the NSF. The pharmacist-led service was more expensive than standard care.

Item Type: Article
Official URL: http://fampra.oxfordjournals.org/
Additional Information: © 2007 The Author
Subjects: R Medicine > R Medicine (General)
R Medicine > RS Pharmacy and materia medica
Sets: Departments > Social Policy
Research centres and groups > LSE Health
Date Deposited: 24 Jun 2011 10:53
Last Modified: 24 Jun 2011 11:07
URI: http://eprints.lse.ac.uk/id/eprint/36999

Actions (login required)

View Item View Item